Back

Eosinophilic Asthma Research Study

Official Title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma

Study Details

The purpose of this study is to evaluate the safety and tolerability of an oral medication in participants with severe asthma while using their regular inhalers.

Principal Investigator

Dr. James Krings

IRB Number

202303199

Eligibility

1. Participants must be at least 18 years old
2. Participants must have asthma and take daily inhaled corticosteroid for at least 3 months
3. Participants must not currently smoke

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back